心瑋醫療-B(06609.HK)公佈年度業績:業務聚焦推動產品結構轉型,毛利率升至70.5%,虧損縮窄,重磅神經介入治療類器械上市在即
格隆匯3月28日丨心瑋醫療-B(06609.HK)公佈年度業績,截至2023年12月31日止年度,公司收入增長至人民幣2.323億元,同比增長26.9%,除税前虧損縮窄至人民幣1.029億元,同比減少48.9%。隨着業務規模擴大和控本增效措施效果的顯現,公司毛利率增長2.6個百分點至70.5%,銷售及分銷開支及行政開支佔比降低至66.2%(2022年:91.8%)。
2023年,為了適應瞬息萬變的市場環境及行業集採的推進,公司不斷推動神經介入業務向治療類器械聚焦的升級。取栓支架及抽吸導管,擴張球囊及栓塞保護系統,以及彈簧圈等神經介入治療類器械貢獻了42.3%的銷售收入,收入金額同比增長62.9%至人民幣9820萬元;神經介入通路器械及其他產品同比增長9.3%至人民幣1.341億元。
2023年,公司研發成本為人民幣1.238億元,用於支持神經介入治療類器械的多元化在研項目。未來24個月,公司預期將有至少5款重磅神經介入治療類器械上市,包括用於狹窄治療的藥物球囊(NMPA創新器械資質)、自膨式藥物支架以及頸動脈支架,用於出血性卒中治療的動脈瘤栓塞輔助支架(NMPA創新器械資質)以及血流導向裝置。同時,公司針對不同亞型腦梗死的急診手術需求,提升關鍵取栓產品(抽吸導管及取栓支架)及一站式醫療器械解決方案的競爭力,以滿足老齡化背景下,中國市場日益增長的腦卒中治療需求。
海外市場方面,公司的取栓支架、封堵球囊導管、遠端通路導管以及微導管已取得CE或FDA認證,並在泰國等國家或地區完成註冊並啟動商業化。截至目前,公司還在10個其他國家或地區開展產品註冊工作,擴展銷售管道,為實現海外銷售的長期目標建立基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.